Home

DOV A MD GOLDSTEIN

CIK 1120478 · Chief Financial Officer · last filed 2026-07-17

DOV A MD GOLDSTEIN is a Chief Financial Officer who has filed 64 SEC Form 4 insider transactions across 9 companies since 2012. The most recent filing, for GANX, was dated Jul 17, 2026. Across all open-market trades the lifetime net is −$37.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $500.4K across reported positions. 2 SEC filings were submitted jointly with AISLING CAPITAL III LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$500.4K

Companies

9

Total Filings

64

Lifetime Open-Market Net

-$37.15M

Filer Profile

Reported Address
C/O BIOAGE LABS, INC.
5885 HOLLIS STREET, SUITE 370
EMERYVILLE, CA 94608
State of Incorporation
DE
Related Filers
AISLING CAPITAL III LP — 2 joint filings, latest 2014-08-06
Aisling Capital Partners III LLC — 2 joint filings, latest 2014-08-06
Aisling Capital Partners III LP — 2 joint filings, latest 2014-08-06
STEVE ELMS — 2 joint filings, latest 2014-08-06
Dennis J Purcell — 2 joint filings, latest 2014-08-06
ANDREW N SCHIFF — 2 joint filings, latest 2014-08-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GANX Director — $1.75 — $0 5 2026-07-17
BIOA Chief Financial Officer 36,575 $8.49 $310.5K -$531.8K 7 2026-04-24
COYA Director 27,557 $4.38 $120.7K $0 6 2026-01-06
NeuBase Therapeutics, Inc. (NBSE) Delisted Director 1,500 $0.38 $567 $158.0K 7 2022-09-12
ADMA Director 7,500 $9.23 $69.2K $0 8 2020-05-01
Esperion Therapeutics, Inc. (ESPR) Delisted Director 1,162,814 $3.18 $3.70M -$53.53M 11 2018-06-08
MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted Director 95 — — $1.39M 14 2017-03-09
Loxo Oncology, Inc. (LOXO) Delisted CFO and Treasurer 3,515,207 — — $5.37M 2 2015-04-03
Durata Therapeutics, Inc. (DRTX) Delisted Director 2,019,713 — — $10.00M 1 2012-07-25

Recent Filings

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-17 GANX Grant (A) — $0 EDGAR
2026-04-24 BIOA Exer (M) +3,542 $15.5K EDGAR
2026-03-03 BIOA Exer (M) +3,542 $15.5K EDGAR
2026-02-19 BIOA Grant (A) — $0 EDGAR
2026-02-03 BIOA Exer (M) +3,541 $15.5K EDGAR
2026-01-21 BIOA Exer (M) +3,542 $15.5K EDGAR
2026-01-15 BIOA Mixed — -$305.3K EDGAR
2026-01-13 BIOA Notice (144) −27,000 -$531.8K EDGAR
2026-01-06 COYA Grant (A) — $0 EDGAR
2025-08-19 COYA Exer (M) +17,557 $19.1K EDGAR
Showing 1–10 of 64
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.